Benzinga -
- RBC Capital Markets has initiated coverage on Repligen Corporation (NASDAQ: RGEN) with a Sector Perform rating and a price target of $190.
- The analyst likes the company due to product differentiation in some of the fastest-growing areas of biopharma.
- But RBC is hesitant towards the stock due to the 12.7x sales multiple, lack of operational earnings beats, declining gross margins, and low absolute R&D investment relative to larger companies in the space.
- Related: Repligen Beefs Up Process Analytics Portfolio With DRS Daylight Solutions Pact.
- Repligen is a pure play in the biopharma production sector, which has exploded over the last 2-3 years and remains the fastest-growing market in life sciences, tools & diagnostics, with first-mover advantage in many product areas.
- But the larger players have taken notice – with M&A and capacity expansion investments, thus concerning the analyst about future growth prospects in what could become a very crowded market.
- Price Action: RGEN shares are up 1.47% at $171.61 on the last check Wednesday.
- Photo Via Company
| Feb 2022 | SVB Leerink | Maintains | Outperform | |
| Oct 2021 | SVB Leerink | Maintains | Outperform | |
| Oct 2021 | Exane BNP Paribas (EPA:BNPP) | Initiates Coverage On | Outperform |
View the Latest Analyst Ratings
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.